Basic helix-loop-helix family member e22 (BHLHE22)

**Basic helix-loop-helix family member e22 (BHLHE22)** is a protein-coding gene encoding a **transcription factor** of the bHLH family, known for regulating cell fate, proliferation, and differentiation[1][3][6]. BHLHE22 does not bind DNA directly despite having an intact basic domain; instead, it inhibits the DNA binding of other bHLH transcription factors such as TCF3/E47 and acts as a strong repressor of Neurod1- and Myod-responsive genes, likely through heterodimerization[1]. In the brain, BHLHE22 may function in the genetic hierarchy guiding neocortical area identity and the survival of inhibitory neurons involved in sensory processing[1]. In model organisms like mice, it plays an essential role in neural development, including retinogenesis and specification of certain neuron subtypes[1][5]. Diseases with genetic associations to BHLHE22 include vertebral hypersegmentation and orofacial anomalies[1]. There is no evidence that BHLHE22 is a therapeutic drug target (such as a receptor, enzyme, transporter, etc.) or that any drugs directly interact with it as a primary pharmacological mechanism. **Clarifying notes:** - BHLHE22 is a transcription factor, not a druggable receptor, enzyme, transporter, or ion channel, so it is not generally considered a therapeutic target[1][5][6]. - There are no clinically relevant drugs or biomarkers directly linked to BHLHE22[1]. - Common aliases include BHLHB5 and TNRC20[1]. - No notable safety concerns or direct disease associations suggest a role for it as a drug target, but it is important in neurodevelopmental biology[1].

Other names

BHLHB5TNRC20